Decreased thalamo-cortico connectivity during an implicit sequence motor learning task and 7 days escitalopram intake.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 07 2021
Historique:
received: 08 01 2021
accepted: 05 07 2021
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 28 10 2021
Statut: epublish

Résumé

Evidence suggests that selective serotonin reuptake inhibitors (SSRIs) reorganize neural networks via a transient window of neuroplasticity. While previous findings support an effect of SSRIs on intrinsic functional connectivity, little is known regarding the influence of SSRI-administration on connectivity during sequence motor learning. To investigate this, we administered 20 mg escitalopram or placebo for 1-week to 60 healthy female participants undergoing concurrent functional magnetic resonance imaging and sequence motor training in a double-blind randomized controlled design. We assessed task-modulated functional connectivity with a psycho-physiological interaction (PPI) analysis in the thalamus, putamen, cerebellum, dorsal premotor, primary motor, supplementary motor, and dorsolateral prefrontal cortices. Comparing an implicit sequence learning condition to a control learning condition, we observed decreased connectivity between the thalamus and bilateral motor regions after 7 days of escitalopram intake. Additionally, we observed a negative correlation between plasma escitalopram levels and PPI connectivity changes, with higher escitalopram levels being associated with greater thalamo-cortico decreases. Our results suggest that escitalopram enhances network-level processing efficiency during sequence motor learning, despite no changes in behaviour. Future studies in more diverse samples, however, with quantitative imaging of neurochemical markers of excitation and inhibition, are necessary to further assess neural responses to escitalopram.

Identifiants

pubmed: 34301974
doi: 10.1038/s41598-021-94009-7
pii: 10.1038/s41598-021-94009-7
pmc: PMC8302647
doi:

Substances chimiques

Serotonin Uptake Inhibitors 0
Citalopram 0DHU5B8D6V

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15060

Informations de copyright

© 2021. The Author(s).

Références

Disabil Rehabil. 2018 Feb;40(3):323-328
pubmed: 27927022
Neuroimage. 2011 Aug 15;57(4):1317-23
pubmed: 21640839
Curr Opin Neurol. 2006 Feb;19(1):84-90
pubmed: 16415682
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):152-159
pubmed: 29409920
Int J Clin Pharmacol Ther. 2020 Aug;58(8):426-438
pubmed: 32449675
Br J Pharmacol. 2004 Jun;142(3):469-78
pubmed: 15148253
J Neurosci. 2000 Dec 15;20(24):9104-10
pubmed: 11124987
J Physiol. 2019 Jan;597(1):271-282
pubmed: 30300446
Neuropsychopharmacology. 2019 Jan;44(1):140-154
pubmed: 30082889
Front Comput Neurosci. 2020 Oct 06;14:554186
pubmed: 33123000
Nat Rev Neurosci. 2005 Mar;6(3):241-6
pubmed: 15738959
Stroke. 2000 Jun;31(6):1360-4
pubmed: 10835457
Int Clin Psychopharmacol. 2006 Mar;21(2):105-10
pubmed: 16421462
J Neurol. 2021 Apr;268(4):1203-1209
pubmed: 31346698
Curr Biol. 2014 Oct 6;24(19):2314-8
pubmed: 25242032
Neuroimage. 2013 Feb 15;67:283-97
pubmed: 23194819
Front Comput Neurosci. 2013 Nov 11;7:163
pubmed: 24273509
Lancet Neurol. 2020 Aug;19(8):661-669
pubmed: 32702335
J Neurosci. 2005 Jun 1;25(22):5356-64
pubmed: 15930384
Behav Brain Res. 2017 Feb 15;319:87-95
pubmed: 27845228
J Neurosci. 2010 Jun 16;30(24):8332-41
pubmed: 20554884
J Neurosci. 2018 Oct 10;38(41):8787-8797
pubmed: 30143573
Hum Brain Mapp. 2020 Jan;41(1):270-286
pubmed: 31520506
J Clin Pharmacol. 2005 Dec;45(12):1400-6
pubmed: 16291715
Neuroimage. 2002 Jan;15(1):26-36
pubmed: 11771971
Soc Cogn Affect Neurosci. 2012 Jun;7(5):604-9
pubmed: 22569188
Magn Reson Med. 1990 Jul;15(1):152-7
pubmed: 2374495
Nucl Med Biol. 2005 Feb;32(2):123-8
pubmed: 15721757
Cold Spring Harb Perspect Biol. 2015 Sep 01;7(9):a021683
pubmed: 26330521
Eur Neuropsychopharmacol. 1999 Dec;9(6):537-44
pubmed: 10625123
J Neurosci. 2019 Apr 3;39(14):2577-2580
pubmed: 30944235
Neuroimage. 2018 May 15;172:107-117
pubmed: 29366697
JAMA Psychiatry. 2013 Sep;70(9):983-9
pubmed: 23842648
Mol Psychiatry. 2009 Nov;14(11):1040-50
pubmed: 18362913
Neuroimage. 1997 Oct;6(3):218-29
pubmed: 9344826
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Brain Struct Funct. 2022 Apr;227(3):793-807
pubmed: 34704176
Neuroimage. 2005 Aug 15;27(2):299-313
pubmed: 15950492
J Neurophysiol. 2017 Aug 1;118(2):1235-1243
pubmed: 28566463
Brain. 1993 Feb;116 ( Pt 1):243-66
pubmed: 8453461
Behav Brain Funct. 2010 Dec 23;6(1):74
pubmed: 21182785
Curr Opin Neurobiol. 2018 Apr;49:33-41
pubmed: 29172091
Cereb Cortex. 2001 Jul;11(7):628-35
pubmed: 11415965
F1000Res. 2019 Jan 30;8:
pubmed: 30755797
PLoS One. 2013 Jun 27;8(6):e68355
pubmed: 23826388
Clin Pharmacokinet. 2007;46(4):281-90
pubmed: 17375980
Hum Brain Mapp. 2020 Sep;41(13):3680-3695
pubmed: 32583940
Neuroimage. 2014 Feb 15;87:170-82
pubmed: 24188812
J Cereb Blood Flow Metab. 2021 Jun;41(6):1449-1462
pubmed: 33148103
Eur Neuropsychopharmacol. 2018 Oct;28(10):1173-1179
pubmed: 30082141
Neurosci Lett. 2001 Jan 26;298(1):65-9
pubmed: 11154837
Neuroimage. 2003 May;19(1):200-7
pubmed: 12781739
Behav Brain Res. 2015 Jun 1;286:136-45
pubmed: 25757996
J Psychopharmacol. 2017 Sep;31(9):1091-1120
pubmed: 28858536
Nature. 2017 May 11;545(7653):181-186
pubmed: 28467817
Brain. 2017 Jan;140(1):218-234
pubmed: 28007998
Psychopharmacology (Berl). 2014 Feb;231(4):623-36
pubmed: 24337875
Curr Opin Neurobiol. 2003 Dec;13(6):663-70
pubmed: 14662366
Elife. 2014 Mar 25;3:e01465
pubmed: 24668166
Lancet Neurol. 2020 Aug;19(8):651-660
pubmed: 32702334
Curr Biol. 2011 Mar 22;21(6):480-4
pubmed: 21376596
Nat Neurosci. 2015 May;18(5):744-51
pubmed: 25849989
Neurosci Biobehav Rev. 2009 Jul;33(7):1004-23
pubmed: 19580915
Front Syst Neurosci. 2012 May 16;6:37
pubmed: 22623914
J Cereb Blood Flow Metab. 1999 Dec;19(12):1365-75
pubmed: 10598941
Brain Behav. 2018 Jun;8(6):e00975
pubmed: 30106253
PLoS One. 2013;8(2):e56133
pubmed: 23418522
Neuroimage. 2012 Feb 1;59(3):2142-54
pubmed: 22019881
Neuroimage. 2014 Mar;88:252-62
pubmed: 24121201
Biol Psychiatry. 2015 Oct 15;78(8):525-33
pubmed: 25497691
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43
pubmed: 22308440
Elife. 2020 May 13;9:
pubmed: 32401193
PLoS One. 2018 Jan 11;13(1):e0190715
pubmed: 29324886

Auteurs

Eóin N Molloy (EN)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. molloy@cbs.mpg.de.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany. molloy@cbs.mpg.de.
International Max Planck Research School NeuroCom, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. molloy@cbs.mpg.de.

Rachel G Zsido (RG)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.
International Max Planck Research School NeuroCom, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Max Planck School of Cognition, Leipzig, Germany.

Fabian A Piecha (FA)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.

Nathalie Beinhölzl (N)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.

Ulrike Scharrer (U)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.

Gergana Zheleva (G)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.

Ralf Regenthal (R)

Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University, Leipzig, Germany.

Bernhard Sehm (B)

Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.
Department of Neurology, University Hospital Halle (Saale), Halle, Germany.

Vadim V Nikulin (VV)

Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.
Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience, National Research University Higher School of Economics, Moscow, Russia.

Harald E Möller (HE)

Nuclear Magnetic Resonance Methods and Development Group, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

Arno Villringer (A)

Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany.
International Max Planck Research School NeuroCom, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
MindBrainBody Institute, Berlin School of Mind and Brain, Charité-Berlin University of Medicine and Humboldt University Berlin, Berlin, Germany.
Clinic of Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany.

Julia Sacher (J)

Emotion and Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. sacher@cbs.mpg.de.
Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1A, 04103, Leipzig, Germany. sacher@cbs.mpg.de.
International Max Planck Research School NeuroCom, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. sacher@cbs.mpg.de.
Max Planck School of Cognition, Leipzig, Germany. sacher@cbs.mpg.de.
Clinic of Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany. sacher@cbs.mpg.de.

Karsten Mueller (K)

Nuclear Magnetic Resonance Methods and Development Group, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH